Jendle Johan, Fang Xin, Cao Yang, Bojö Leif, Nilsson Bo K, Hedberg Fredric, Santos-Pardo Irene, Nyström Thomas
Institution of Medical Sciences, Örebro University, Örebro, Sweden.
Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
J Am Soc Hypertens. 2018 May;12(5):346-355. doi: 10.1016/j.jash.2018.02.003. Epub 2018 Feb 16.
In this post hoc study, we aimed to investigate liraglutide treatment on repetitive 24-hour blood pressure (BP) in patients with type II diabetes. Sixty-two individuals with type II diabetes (45 males) were randomized to 1.8 mg liraglutide once daily or 4 mg glimepiride together with 1 g metformin twice daily. Ambulatory 24-hour systolic and diastolic blood pressure (sBP/dBP) was repetitively measured at baseline, 2 weeks, and 18 weeks. Outcomes were evaluated as treatment change from baseline, 2 weeks, and 18 weeks. Baseline clinical characteristics of liraglutide (n = 33) and glimepiride (n = 29) groups were well matched. No statistically significant difference in 24-hour sBP/dBP between three time periods and groups was observed. There was no treatment change for 24-hour sBP at week 2 or after week 18. There was a transient treatment change in 24-hour dBP in the liraglutide group at week 2 (3.2 ± 5.4 vs. -1.2 ± 4.5 mm Hg, P < .01). A treatment change in 24-hour heart rate at week 2 (4.9 ± 6.8 vs. 1.0 ± 6.0 bpm, P = .03) and at week 18 (5.9 ± 7.8 vs. 0.2 ± 6.3 bpm, P < .01) was observed in the liraglutide group. In conclusion, liraglutide treatment did not lower BP. However, a small diurnal variation in dBP without affecting BP variability or nocturnal BP dipping was observed.
在这项事后分析研究中，我们旨在调查利拉鲁肽治疗对2型糖尿病患者24小时重复性血压（BP）的影响。62例2型糖尿病患者（45例男性）被随机分为两组，一组每日一次皮下注射1.8mg利拉鲁肽，另一组每日两次口服4mg格列美脲及1g二甲双胍。在基线期、2周和18周重复测量24小时动态收缩压和舒张压（sBP/dBP）。评估指标为治疗后相对于基线期、2周和18周时的变化。利拉鲁肽组（n = 33）和格列美脲组（n = 29）的基线临床特征匹配良好。三个时间段及两组间24小时sBP/dBP无统计学显著差异。在第2周及18周后，24小时sBP无治疗差异。利拉鲁肽组在第2周时24小时dBP有短暂治疗差异（3.2±5.4 vs. -1.2±4.5 mmHg，P < 0.01）。利拉鲁肽组在第2周（4.9±6.8 vs. 1.0±6.0次/分钟，P = 0.03）和第18周（5.9±7.8 vs. 0.2±6.3次/分钟，P < 0.01）观察到24小时心率有治疗差异。总之，利拉鲁肽治疗未降低血压。然而，观察到dBP有小的昼夜变化，且未影响血压变异性或夜间血压谷峰差值。
